Sociedad Americana de Hirudoterapia

Cardiopulmonary bypass in humans: bypassing unfractionated heparin.

Review published in The Annals of thoracic surgery (2000)

Última actualización: June 18, 2026Revisado por: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Narrative reviewEnsayos clínicosDesarrollo de fármacosFrederiksen · The Annals of thoracic surgery, 2000

Abstract

Seven anticoagulants besides unfractionated heparin have been used for human cardiopulmonary bypass (CPB), mainly in patients with heparin-induced thrombocytopenia. The collective experience with these alternative anticoagulants provides a perspective on current efforts aimed at improving CPB anticoagulation. Unfortunately, each alternative currently lacks a standard dosing schedule and a reliable method of monitoring the adequacy of its anticoagulant effect during CPB. Most also lack proven antidotes. Thus, unfractionated heparin remains the anticoagulant of choice for standard CPB.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal ArticleReview
Indexed MeSH termsAnticoagulantsCardiopulmonary BypassDose-Response Relationship, DrugDrug Administration ScheduleHeparinHumansThrombocytopenia

Resumen

Seven anticoagulants besides unfractionated heparin have been used for human cardiopulmonary bypass (CPB), mainly in patients with heparin-induced thrombocytopenia. The collective experience with these alternative anticoagulants provides a perspective on current efforts aimed at improving CPB anticoagulation.

Por qué esto importa para la hirudoterapia

This review discusses seven anticoagulants used as alternatives to unfractionated heparin during human cardiopulmonary bypass, primarily in patients with heparin-induced thrombocytopenia. The authors note that each alternative currently lacks a standard dosing schedule, a reliable monitoring method for anticoagulant adequacy during bypass, and, in most cases, a proven antidote, leaving unfractionated heparin as the anticoagulant of choice for standard cardiopulmonary bypass. The abstract does not mention leeches, hirudin, hirudotherapy, or any leech-derived molecules. The article's connection to the American Society of Hirudotherapy is therefore nonexistent based on the abstract alone, as it focuses entirely on conventional anticoagulant alternatives for surgical bypass.

Citación

Cardiopulmonary bypass in humans: bypassing unfractionated heparin.

Frederiksen · The Annals of thoracic surgery, 2000

Contexto clínico relacionado

Añadido a la biblioteca ASH: May 28, 2026 · Última actualización del sitio: June 18, 2026

Este sitio web proporciona información educativa y no constituye consejo médico, diagnóstico ni recomendaciones de tratamiento. La terapia con sanguijuelas medicinales conlleva riesgos clínicamente significativos y debe ser realizada únicamente por profesionales calificados bajo protocolos aprobados institucionalmente. La autorización 510(k) de la FDA para sanguijuelas medicinales se limita a indicaciones específicas; las discusiones sobre uso investigativo y fuera de indicación se señalan correspondientemente. Para orientación médica específica, consulte a un profesional de salud calificado.